4.4 Article

The Potential Association Between Postmenopausal Hormone Use and Primary Open-Angle Glaucoma

期刊

JAMA OPHTHALMOLOGY
卷 132, 期 3, 页码 298-303

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jamaophthalmol.2013.7618

关键词

-

资金

  1. National Eye Institute K23 Mentored Clinician Scientist Award [1K23EY019511-01]
  2. American Glaucoma Society Clinician Scientist Grant
  3. Blue Cross Blue Shield of Michigan Foundation
  4. Research to Prevent Blindness
  5. Heed Foundation Fellowship
  6. National Eye Institute Core Grant [EY07003]
  7. National Eye Institute [RO1 EY015473]
  8. Harvard Glaucoma Center of Excellence, the Margolis Fund
  9. Arthur Ashley Foundation

向作者/读者索取更多资源

IMPORTANCE Retinal ganglion cells are known to express estrogen receptors and prior studies have suggested an association between postmenopausal hormone (PMH) use and decreased intraocular pressure, suggesting that PMH use may decrease the risk for primary open-angle glaucoma (POAG). OBJECTIVE To determine whether the use of 3 different classes of PMH affects the risk for POAG. DESIGN, SETTING, AND PARTICIPANTS Retrospective longitudinal cohort analysis of claims data from women 50 years or older enrolled in a US managed-care plan for at least 4 years in which enrollees had at least 2 visits to an eye care provider during the period 2001 through 2009. EXPOSURE Postmenopausal hormone medications containing estrogen only, estrogen + progesterone, and estrogen + androgen, as captured from outpatient pharmacy claims over a 4-year period. MAIN OUTCOMES AND MEASURES Hazard ratios (HRs) for developing incident POAG. RESULTS Of 152 163 eligible enrollees, 2925 (1.9%) developed POAG. After adjustment for confounding factors, each additional month of use of PMH containing estrogen only was associated with a 0.4% reduced risk for POAG (HR, 0.996 [95% CI, 0.993-0.999]; P = .02). The risk for POAG did not differ with each additional month of use of estrogen + progesterone (HR, 0.994 [95% CI, 0.987-1.001]; P = .08) or estrogen + androgen (HR, 0.999 [95% CI, 0.988-1.011]; P = .89). CONCLUSIONS AND RELEVANCE Use of PMH preparations containing estrogen may help reduce the risk for POAG. If prospective studies confirm the findings of this analysis, novel treatments for this sight-threatening condition may follow.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据